$SOC

Sable Offshore (NYSE:SOC) CEO Jim Flores was Houston's highest-paid executive in 2025, with $76 million in total compensation, including $69 million in stock awards, amid a federal insider trading probe. Social Security treats salary, bonuses, and stock awards differently for tax and benefit purposes, affecting earnings records and benefits.

Sable Offshore Corp. (SOC) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Sable Offshore Corp. Provides Operational Update Houston, September 28, 2026 – Sable Offshore Corp. (“Sable”) (NYSE: SOC) today provides the following operational update focused on the pending restart of Platform Hondo, ongoing Las Flores Canyon Midstream Processing

Stifel highlights four oil and gas stocks: Diamondback Energy (FANG), Expand Energy (EXE), Permian Resources (PR), and Sable Offshore (SOC). The sector benefits from high energy prices, capital discipline, and growing demand. FANG and PR reported strong Q2 2026 results, with mixed analyst reactions for FANG and a price target increase for PR.

SOC, HTZ, and COSM stocks fell to 52-week lows. SOC dropped 56% after a $450M offering plan. HTZ declined 1.5% due to price target cuts. COSM initially fell but closed up 5.54% after a $5M share buyback plan. SOC and HTZ have declined 73% and 56% this year, respectively, while COSM is down 64.48%.

Sable Offshore Corp. (SOC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sable Offshore Corp. Reports Second Quarter 2026 Financial and Operational Results Houston, August 10, 2026 – Sable Offshore Corp. (“Sable,” or the “Company”) (NYSE: SOC) today announced its second quarter 2026 financial and operational results. Second Quarter 2026 F

The Russell 2000 stayed near 3,000 with little movement, while seven small-cap stocks gained at least 28% in four sessions. The article cites July surges for Orthofix (OFIX) on CMS reimbursement reversal, REGENXBIO (RGNX) on FDA resubmission alignment and AbbVie milestone, Verastem (VSTM) on short-squeeze setup, ADC Therapeutics (ADCT) rebound, Sable Offshore (SOC) refinancing, Rapid7 (RPD) takeover speculation, and Crinetics (CRNX) surge toward an offer price.

Sable Offshore Corp. (NYSE:SOC) received rating updates on July 6. Gerdes Energy Research upgraded SOC to Buy from Neutral and set a $8 price target, down from $11, citing new equity capitalization and convertible debt. Jefferies maintained a Buy but cut its target to $11 from $24, citing a challenging period and dilution, with refinancing complete ahead of a July court ruling.

Jefferies cut Sable Offshore Corp. (NYSE:SOC) price target from $24 to $11 on July 6 while keeping a Buy rating, citing over 180% upside versus the target. The company also disclosed a July 1 public offering of 32.47M shares at $3.08 and $300M 6.5% convertible notes due 2031, plus options for additional shares and notes.

Sable Offshore Corp. (SOC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.2 9 ex102-xseniorrevolvercredi.htm EX-10.2 Document Exhibit 10.2 Revolving Credit Agreement dated as of July 2, 2026 among Sable Offshore Corp., as Borrower, JPMorgan Chase Bank, N.A., as Administrative Agent, and The Lenders Party Hereto as Lead Arranger and Bookrunner TAB

Sable Offshore Corp. (SOC) said it plans to raise $100 million via a common stock offering and $300 million via convertible senior notes due 2031. Shares fell about 52% to $3.34 on the NYSE from $6.97 prior close, after the announcement.